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benign and malignant cases. Results: In 2008-2009 there were 477904 screening 
mammography examinations in Hungary. 5.15 % of participating women were re-
called. The attendance of re-called women was 92.25 %. Altogether 2092 women 
(9.7 %) were referred for breast surgery but only 1485 women (71.0 %) underwent 
surgery. Histological examination confirmed 281 benign (18.9 %) and 1204 malignant 
(81.1 %) cases. ConClusions: The quality indicators of the Hungarian organized 
mammography screening program met the recommendations of international pro-
fessional guidelines. However, in addition to current indicators, new ones should be 
introduced in order to provide a more comprehensive monitoring of the program.
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objeCtives: Organized, nationwide screening for breast cancer with mammog-
raphy started in Hungary in January 2002. Women in the age group 45-65 years 
are the target population and 2 years screening interval is applied. The aim of 
this study is to analyze the attendance rate of the 4th screening round (2008-
2009). Methods: The data derive from the financial database of the National 
Health Insurance Fund Administration (NHIFA) covering the period of 2008-2009. 
We calculated two attendance indicators. The up-take of the program means 
the percentage of women aged 45-65 who, having been sent an invitation for 
screening, attend a screening unit and undergo mammography in response to 
that invitation. We defined coverage as the ratio of women in the age group 
45-65 years having either a screening mammography or a diagnostic mam-
mography. Results: In 2008-2009 there were 477904 screening mammography 
cases and 1204893 diagnostic mammography examinations in Hungary. We found 
49.4 % and 41.5 % up-take in 2008 and 2009 respectively; and 45.0 % combined 
rate for 2008/2009. The screening coverage was 31.2 % and the diagnostic cover-
age was 20.4 %, while the total coverage (screening and diagnostic) was 50.1 
%. ConClusions: The attendance of the Hungarian organized breast cancer 
screening program – compared to the previous period before the implementa-
tion of the organized screening program – is promising, although to achieve the 
expected results in mortality decrease a further improvement of both the uptake 
and coverage is necessary.
PCN27
rACiAl diSPAriTieS iN diffuSioN, ComPArATive morBidiTy, ANd diSeASe 
CoNTrol of iNTeNSiTy-modulATed rAdiATioN TherAPy ComPAred To 
CoNformAl rAdiATioN TherAPy for loCAlized ProSTATe CANCer
Cobran E.K.1, Overman R.2, Carpenter W.R.3, Godley P.A.4, Chen R.5
1University of North Carolina at Chapel Hill, Gillings School of Global Public Health and School 
of Medicine, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA, 2University 
of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Division of Pharmaceutical 
Outcomes and Policy, Chapel Hill, NC, USA, 3University of North Carolina at Chapel Hill, Gillings 
School of Global Public Health Department of Health Policy and Management, Chapel Hill, NC, 
USA, 4University of North Carolina at Chapel Hill, School of Medicine, Division of Hematology/
Oncology, Chapel Hill, NC, USA, 5University of North Carolina at Chapel Hill, School of Medicine, 
Department of Radiation Oncology and Urology, Chapel Hill, NC, USA
objeCtives: Recent advances in prostate cancer radiation therapy (RT) technology 
have led to the development of costlier treatments such as intensity-modulated 
radiation therapy (IMRT) compared to the prior standard, conventional radiation 
therapy (CRT). This study examines the two treatment modalities to determine if 
racial disparities in morbidity and disease control may be explained by differential 
use of IMRT versus CRT. Methods: A population-based study was conducted 
using Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data 
from 2000 through 2009 for patients with non-metastatic prostate cancer. Adjusted 
Cox Proportional Hazards models were conducted, adjusting for demographic 
and clinical characteristics. Results are presented as (Adjusted Hazard Ratio [95% 
Confidence Interval]). In subjects without prior morbidity at RT, the rate of recur-
rence, hip fracture, erectile dysfunction, disorders related to gastrointestinal, 
and urinary (incontinence and non-incontinence) morbidity were compared by 
race with IMRT as the referent group. Results: Approximately 10,976 men [524 
African-American (AA) CRT; 423 AA IMRT; 4,746 Caucasian CRT; 5,283 Caucasian 
IMRT] met study eligibility. Diffusion of IMRT was slower among AA compared 
to Caucasians (p< 0.001). Caucasians receiving CRT were at a greater risk for hip 
fracture [1.29; (1.16, 1.43)], cancer recurrence [1.13; (1.04, 1.23)], or urinary incon-
tinence [1.09; (1.01, 1.19)] than those receiving IMRT. No estimates comparing 
AA CRT recipients to AA IMRT recipients reached statistical significance, though 
cancer recurrence, erectile dysfunction, and gastrointestinal morbidity rates were 
greater for CRT subjects ConClusions: There were no statistically significant 
racial disparities in morbidity and disease control related to differential use of 
IMRT versus CRT. However, diffusion of IMRT was significantly slower among AA. 
Future research should include more years of follow-up data and a larger sample 
of AA in order to understand whether measured differences in treatment diffusion 
achieve clinical significance sufficient to explain a portion of the racial disparity 
in prostate cancer mortality.
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comparisons. ConClusions: Current standards around second-line treatment of 
mCRC have evolved over time. The substantial clinical, methodological, and sta-
tistical heterogeneity in the available data prevents evidence-based quantitative 
comparisons of treatment outcomes at this time.
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objeCtives: This study compares everolimus (EVE) versus the most commonly 
used chemotherapy agents in UK clinical practice (capecitabine [CAPE], docetaxel 
[DOC] and doxorubicin [DOX]) in patients with hormone receptor positive, HER2 
negative advanced or metastatic breast cancer with the purpose of determining 
the effect of everolimus versus chemotherapy through the derivation of hazard 
ratios (HR). Methods: A systematic review of the literature was performed to find 
evidence that could link EVE with chemotherapy (CAPE, DOC and DOX) in terms 
of progression-free survival (PFS) and overall survival (OS). No head-to-head tri-
als comparing EVE versus chemotherapy were found, the only study that linked 
hormonal therapy with chemotherapy for treatment of metastatic breast cancer 
was Wilcken et al. (2003). Wilcken et al. identified three studies which compared 
OS for tamoxifen versus chemotherapy. None of the studies identified in the sys-
tematic review reported PFS. The link between EVE versus chemotherapy through 
Wilcken et al.(2003) was established via tamoxifen (using Bucher methods), so it 
was assumed that PFS for chemotherapy would be the same as PFS for everolimus 
versus tamoxifen (TAM) from the TAMRAD trial. Results: HR for everolimus versus 
tamoxifen for PFS from the TAMRAD trial is 0.54. For OS, Wilcken et al. derived a HR 
for chemotherapy versus tamoxifen of 0.94. To calculate the HR for OS for everoli-
mus vs tamoxifen the inverse was applied to the OS HR from the TAMRAD trial 
(0.45), hence (1/0.45)= 2.22. The HR for OS for everolimus versus chemotherapy is 
therefore (0.94x2.22)= 2.09. Because a class effect was assumed for the three chemo-
therapy agents, these HRs were applied to capecitabine, docetaxel and doxorubicin 
equally. ConClusions: Compared with the most commonly used chemotherapy 
agents in UK clinical practice (CAPE, DOC and DOX), everolimus has a lower risk of 
death as demonstrated by the HRs derived.
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objeCtives: Lung cancer is the most common cause of cancer-related deaths 
world-wide. Afatinib is a novel, potent, irreversible ErbB family blocker. In EGFR 
mutation-positive locally advanced and metastatic non-small cell lung cancer, 
afatinib shows superior effectiveness as a 1st-line treatment compared to stand-
ard-of-care chemotherapy. To date, no head-to-head trial results exist to compare 
the efficacy of afatinib to reversible EGFR TKIs, gefitinib or erlotinib. The analy-
ses presented here attempt to fill this gap by means of a network meta-analysis 
(NMA). Methods: A systematic literature review (2002-2012) identified the best 
available evidence. Results from afatinib’s pivotal trials (LUX-Lung 3, LUX-Lung 6) 
were added. A NMA following a Bayesian approach (in WinBUGS) was applied to 
estimate the relative treatment effects between afatinib, gefitinib and erlotinib. 
Outcomes of interest were progression free survival (PFS) and overall survival (OS). 
For PFS, results by investigator review were considered as not in all trials PFS was 
assessed independently. Versus erlotinib, afatinib’s results in the two most common 
EGFR mutations studied in erlotinib trials were considered. Sensitivity analyses were 
performed to confirm the robustness of results. Results: Twenty studies, includ-
ing LUX-Lung 3 and LUX-Lung 6, were included; 19 reported OS, 14 reported PFS. 
Results from random effects models are reported. All comparisons versus reversible 
TKIs favoured afatinib, although in most analyses the upper credible interval limit 
exceeded 1. The estimated probability of afatinib being best regarding PFS in all 
mutations was 80% compared to 17% for erlotinib and 3% for gefitinib, and was 43% 
regarding OS compared to 13% for gefitinib and 3% for erlotinib. ConClusions: 
Afatinib consistently showed superior efficacy versus chemotherapy in the pivotal 
trials. In the absence of head-to-head trial results versus reversible TKIs, the NMA 
results suggest also potential superiority of afatinib for both PFS and OS when 
compared to erlotinib and gefitinib.
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objeCtives: Organized, nationwide screening for breast cancer with mammogra-
phy started in Hungary in January 2002. Women in the age group 45-65 years are the 
target population and 2 years screening interval is applied. The aim of this study is 
to evaluate the quality indicators of the 4th screening round (2008-2009). Methods: 
The data derive from the financial database of the National Health Insurance Fund 
Administration (NHIFA) covering the period of 2008-2009. We calculated the follow-
ing indicators: recall rate of women who underwent mammography examinations, 
attendance of re-called women, proportion of women referred to surgery, proportion 
of women who underwent surgery compared to referred women, proportion of 
